Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda.
Pregnancy alters the pharmacokinetic properties of many antimalarial compounds. The objective of this study was to evaluate the pharmacokinetic properties of lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Uganda after a standard fixed oral artemeth...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2013
|
| _version_ | 1797091338626269184 |
|---|---|
| author | Kloprogge, F Piola, P Dhorda, M Muwanga, S Turyakira, E Apinan, S Lindegårdh, N Nosten, F Day, N White, N Guerin, P Tarning, J |
| author_facet | Kloprogge, F Piola, P Dhorda, M Muwanga, S Turyakira, E Apinan, S Lindegårdh, N Nosten, F Day, N White, N Guerin, P Tarning, J |
| author_sort | Kloprogge, F |
| collection | OXFORD |
| description | Pregnancy alters the pharmacokinetic properties of many antimalarial compounds. The objective of this study was to evaluate the pharmacokinetic properties of lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Uganda after a standard fixed oral artemether-lumefantrine treatment. Dense venous (n = 26) and sparse capillary (n = 90) lumefantrine samples were drawn from pregnant patients. A total of 17 nonpregnant women contributed with dense venous lumefantrine samples. Lumefantrine pharmacokinetics was best described by a flexible absorption model with multiphasic disposition. Pregnancy and body temperature had a significant impact on the pharmacokinetic properties of lumefantrine. Simulations from the final model indicated 27% lower day 7 concentrations in pregnant women compared with nonpregnant women and a decreased median time of 0.92 and 0.42 days above previously defined critical concentration cutoff values (280 and 175 ng/ml, respectively). The standard artemether-lumefantrine dose regimen in P. falciparum malaria may need reevaluation in nonimmune pregnant women.CPT: Pharmacometrics and Systems Pharmacology (2013) 2, e83; doi:10.1038/psp.2013.59; advance online publication 13 November 2013. |
| first_indexed | 2024-03-07T03:31:34Z |
| format | Journal article |
| id | oxford-uuid:bae9c035-f799-41f2-a1fc-0013105cc304 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:31:34Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:bae9c035-f799-41f2-a1fc-0013105cc3042022-03-27T05:13:03ZPopulation Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:bae9c035-f799-41f2-a1fc-0013105cc304EnglishSymplectic Elements at Oxford2013Kloprogge, FPiola, PDhorda, MMuwanga, STuryakira, EApinan, SLindegårdh, NNosten, FDay, NWhite, NGuerin, PTarning, JPregnancy alters the pharmacokinetic properties of many antimalarial compounds. The objective of this study was to evaluate the pharmacokinetic properties of lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Uganda after a standard fixed oral artemether-lumefantrine treatment. Dense venous (n = 26) and sparse capillary (n = 90) lumefantrine samples were drawn from pregnant patients. A total of 17 nonpregnant women contributed with dense venous lumefantrine samples. Lumefantrine pharmacokinetics was best described by a flexible absorption model with multiphasic disposition. Pregnancy and body temperature had a significant impact on the pharmacokinetic properties of lumefantrine. Simulations from the final model indicated 27% lower day 7 concentrations in pregnant women compared with nonpregnant women and a decreased median time of 0.92 and 0.42 days above previously defined critical concentration cutoff values (280 and 175 ng/ml, respectively). The standard artemether-lumefantrine dose regimen in P. falciparum malaria may need reevaluation in nonimmune pregnant women.CPT: Pharmacometrics and Systems Pharmacology (2013) 2, e83; doi:10.1038/psp.2013.59; advance online publication 13 November 2013. |
| spellingShingle | Kloprogge, F Piola, P Dhorda, M Muwanga, S Turyakira, E Apinan, S Lindegårdh, N Nosten, F Day, N White, N Guerin, P Tarning, J Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda. |
| title | Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda. |
| title_full | Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda. |
| title_fullStr | Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda. |
| title_full_unstemmed | Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda. |
| title_short | Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda. |
| title_sort | population pharmacokinetics of lumefantrine in pregnant and nonpregnant women with uncomplicated plasmodium falciparum malaria in uganda |
| work_keys_str_mv | AT kloproggef populationpharmacokineticsoflumefantrineinpregnantandnonpregnantwomenwithuncomplicatedplasmodiumfalciparummalariainuganda AT piolap populationpharmacokineticsoflumefantrineinpregnantandnonpregnantwomenwithuncomplicatedplasmodiumfalciparummalariainuganda AT dhordam populationpharmacokineticsoflumefantrineinpregnantandnonpregnantwomenwithuncomplicatedplasmodiumfalciparummalariainuganda AT muwangas populationpharmacokineticsoflumefantrineinpregnantandnonpregnantwomenwithuncomplicatedplasmodiumfalciparummalariainuganda AT turyakirae populationpharmacokineticsoflumefantrineinpregnantandnonpregnantwomenwithuncomplicatedplasmodiumfalciparummalariainuganda AT apinans populationpharmacokineticsoflumefantrineinpregnantandnonpregnantwomenwithuncomplicatedplasmodiumfalciparummalariainuganda AT lindegardhn populationpharmacokineticsoflumefantrineinpregnantandnonpregnantwomenwithuncomplicatedplasmodiumfalciparummalariainuganda AT nostenf populationpharmacokineticsoflumefantrineinpregnantandnonpregnantwomenwithuncomplicatedplasmodiumfalciparummalariainuganda AT dayn populationpharmacokineticsoflumefantrineinpregnantandnonpregnantwomenwithuncomplicatedplasmodiumfalciparummalariainuganda AT whiten populationpharmacokineticsoflumefantrineinpregnantandnonpregnantwomenwithuncomplicatedplasmodiumfalciparummalariainuganda AT guerinp populationpharmacokineticsoflumefantrineinpregnantandnonpregnantwomenwithuncomplicatedplasmodiumfalciparummalariainuganda AT tarningj populationpharmacokineticsoflumefantrineinpregnantandnonpregnantwomenwithuncomplicatedplasmodiumfalciparummalariainuganda |